Navigation Links
Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
Date:7/25/2008

- Management to discuss second quarter financial results -

LAVAL, QC, July 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, August 8 at 8:30 a.m. (ET) to discuss its second quarter 2008 financial results. Labopharm will report its second quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-646-3095 or 1-800-814-4859. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 15, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21278611 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which re
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
2. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
3. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
4. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
5. Labopharm Reports Results for First Quarter Fiscal 2008
6. Labopharm announces details for first quarter results conference call and annual meeting
7. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
8. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
9. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
10. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
11. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... ROCKVILLE, Md., March 5 Americans and nonprofit organizations ... of these circumstances, The Larry King Cardiac Foundation (LKCF), ... for individuals with no health insurance, has announced that ... 2009.In lieu of its annual black tie gala held ...
... happens may lead to ways around it, researchers say, ... standard treatment for brain cancer, may boost the aggressiveness ... a new study suggests. , The research team, from ... identified cells in brain tumors called gliomas that have ...
... response to a recent report by the National Council ... U.S. population is exposed to seven times more radiation ... Americans to consider the proven benefits of such imaging. ... technologists support the use of diagnostic imaging when deemed ...
... WASHINGTON, March 5 Stephen J. Ubl, president and CEO ... the Medical Device Safety Act to be introduced today in Congress. If ... , Chill innovation and ... Dramatically alter the regulatory environment for certain medical devices, ...
... March 5 Stephen J. Ubl, president ... released the following statement today regarding the re-introduction of ... not in any way improve patient safety. It will, ... a chilling effect on medical innovation, create more lawsuits ...
... Dialysis Corporation of America (Nasdaq: DCAI ) announced its financial ... , , ... dialysis center acquired December 31, 2008. , ... $23.7 million compared to $20.0 million for the same period last year, ...
Cached Medicine News:Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 2Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 3Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Medical imaging benefits far outweigh radiation risks 2Health News:AdvaMed Response to the Medical Device Safety Act 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 3Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 4Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 5Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 6Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 7Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 8
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Novavax, Inc. (Nasdaq: NVAX ), a clinical-stage vaccine ... Novavax, will be presenting at the ROTH 23rd Annual OC ... local time at The Ritz Carlton, Laguna Niguel, CA.  A ... via the Company website at www.novavax.com under Investors/Events, ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, ... financial results for the fourth quarter and year ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "I am energized and ...
Cached Medicine Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Bipolar forceps...
... the pathologist to visualize the presence of Human ... a choice of sample types: tissue, monolayer-based preparations, ... proprietary probe formulations. The Family 16 probe cocktail ... 31, 33, 35, 39, 51, 52, 56, 58, ...
... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
Medicine Products: